PTCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
PTC THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$61.53+2.29 (+3.87%)
Close on Oct 19, 2026
- Market cap
- $5.66B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
100M of 83M shares
Institutional holders
382
77 new, 44 sold out
Net institutional buying
12M
In Q2 2026
Insider trades, 12 months
0 buys · 198 sales
Net sold $56.63M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Roderick Wong, M.D | 7,423,970 | 9.80% | 13G (passive) amendment | Dec 31, 2023 |
| Janus Henderson Group PLC | 7,193,433 | 8.70% | 13G (passive) amendment | Mar 31, 2026 |
| Vanguard Portfolio Management | 4,871,329 | 5.88% | 13G (passive) | Mar 31, 2026 |
| Wellington Management Company LLP | 4,787,123 | 6.10% | 13G (passive) amendment | Dec 31, 2024 |
| Steven Boyd | 4,735,464 | 5.96% | 13G (passive) amendment | Jun 30, 2025 |
| Vanguard Capital Management | 4,284,448 | 5.17% | 13G (passive) | Mar 31, 2026 |
| State Street Corporation | 4,206,126 | 5.20% | 13G (passive) | Dec 31, 2025 |
| BlackRock, Inc. | 11,904,696 | 14.80% | 13G (passive) amendment | Nov 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PTCT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 13,964,554 | 16.73% | $1.14B | +1,015,837 | 0.02% |
| Rtw Investments, LP | 7,746,415 | 9.28% | $631.88M | – | 5.39% |
| Jupiter Topco LLC | 7,236,402 | 8.67% | $590.18M | New | 0.24% |
| Vanguard Portfolio Management LLC | 4,928,111 | 5.90% | $401.99M | +123,517 | 0.02% |
| State Street Corp | 4,598,952 | 5.51% | $375.14M | +252,433 | 0.01% |
| Wellington Management Group Llp | 4,128,273 | 4.95% | $336.74M | +185,663 | 0.06% |
| Vanguard Capital Management LLC | 3,739,127 | 4.48% | $305.00M | +62,871 | 0.01% |
| Geode Capital Management, LLC | 2,207,376 | 2.64% | $180.09M | −2,578 | 0.01% |
| Toronto Dominion Bank | 2,165,846 | 2.60% | $176.67M | −860,117 | 0.20% |
| Westfield Capital Management Co LP | 1,956,156 | 2.34% | $159.56M | New | 0.52% |
| Hood River Capital Management LLC | 1,738,613 | 2.08% | $141.82M | +74,054 | 1.03% |
| William Blair Investment Management, LLC | 1,722,688 | 2.06% | $140.52M | New | 0.42% |
| D. E. Shaw & Co., Inc. | 1,548,919 | 1.86% | $126.35M | −91,462 | 0.06% |
| Tang Capital Management LLC | 1,500,000 | 1.80% | $122.36M | – | 5.56% |
| Bank Of America Corp /De/ | 1,452,277 | 1.74% | $118.46M | −434,564 | 0.01% |
| Driehaus Capital Management LLC | 1,440,107 | 1.73% | $117.47M | +424,335 | 0.68% |
| FMR LLC | 1,398,261 | 1.68% | $114.06M | −130,101 | 0.00% |
| Jefferies Financial Group Inc. | 1,357,042 | 1.63% | $110.69M | +2,583 | 0.73% |
| Fuller & Thaler Asset Management, Inc. | 1,156,819 | 1.39% | $94.36M | New | 0.26% |
| Pictet Asset Management Holding SA | 1,147,844 | 1.38% | $93.63M | −35,876 | 0.09% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 382 | 100M | 100.0% | 77 / 142 | 113 / 44 | 21M | 9M |
| Q1 2026 | 352 | 96M | 100.0% | 61 / 145 | 102 / 56 | 21M | 9M |
| Q4 2025 | 353 | 93M | 100.0% | 101 / 127 | 96 / 37 | 19M | 9M |
| Q3 2025 | 294 | 83M | 99.7% | 55 / 101 | 105 / 41 | 13M | 10M |
| Q2 2025 | 284 | 81M | 96.6% | 60 / 111 | 80 / 35 | 11M | 9M |
| Q1 2025 | 261 | 79M | 94.5% | 51 / 85 | 93 / 27 | 11M | 9M |
| Q4 2024 | 240 | 78M | 93.2% | 56 / 77 | 78 / 17 | 11M | 12M |
| Q3 2024 | 203 | 79M | 95.1% | 31 / 70 | 70 / 26 | 12M | 5M |
| Q2 2024 | 199 | 81M | 96.5% | 45 / 78 | 62 / 27 | 5M | 14M |
| Q1 2024 | 184 | 90M | 100.0% | 34 / 53 | 69 / 22 | 10M | 7M |
| Q4 2023 | 173 | 87M | 100.0% | 26 / 72 | 56 / 30 | 18M | 13M |
| Q3 2023 | 180 | 81M | 97.3% | 23 / 81 | 58 / 46 | 11M | 10M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of PTCT | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 4,997,138 | 5.99% | $407.62M | 0.37% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 2,635,817 | 3.16% | $215.00M | 0.01% | Jun 30, 2026 |
| Vanguard Health Care Fund | 2,310,268 | 2.77% | $157.12M | 0.41% | Jul 31, 2026 |
| iShares Russell 2000 ETF | 2,127,944 | 2.55% | $173.58M | 0.21% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 1,902,975 | 2.28% | $155.23M | 0.08% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,357,466 | 1.63% | $110.73M | 1.03% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,096,792 | 1.31% | $89.47M | 0.19% | Jun 30, 2026 |
| Janus Henderson Global Life Sciences Fund | 995,577 | 1.19% | $81.21M | 1.40% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 951,394 | 1.14% | $77.61M | 0.08% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 905,253 | 1.08% | $61.57M | 0.18% | Jul 31, 2026 |
| Hood River Small-Cap Growth Fund | 832,255 | 1.00% | $67.89M | 1.02% | Jun 30, 2026 |
| Fullerthaler Behavioral Small-Cap Growth | 780,300 | 0.93% | $63.65M | 1.03% | Jun 30, 2026 |
| State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF | 762,247 | 0.91% | $62.18M | 0.37% | Jun 30, 2026 |
| iShares S&P Small-Cap 600 Growth ETF | 745,407 | 0.89% | $60.80M | 0.74% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 653,446 | 0.78% | $53.30M | 0.35% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Matthew B. Klein | CHIEF EXECUTIVE OFFICER, Director | 383,868 | 0.46% | Aug 6, 2026 |
| Mark Elliott Boulding | EXEC. VP AND CLO | 106,241 | 0.13% | Aug 19, 2026 |
| Pierre Gravier | CHIEF FINANCIAL OFFICER | 83,986 | 0.10% | Jul 16, 2026 |
| Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFICER | 65,662 | 0.08% | Jul 13, 2026 |
| Christine Marie Utter | SVP, CHIEF ACCOUNTING OFFICER | 70,199 | 0.08% | Jun 22, 2026 |
| Eric Pauwels | CHIEF BUSINESS OFFICER | 90,977 | 0.11% | Jun 12, 2026 |
| Lee Scott Golden | EVP & CHIEF MEDICAL OFFICER | 79,115 | 0.09% | Apr 6, 2026 |
| Michael Schmertzler | Director | 1,460,236 | 1.75% | Sep 18, 2026 |
| Hege Elisabeth Sollie-Zetlmayer | Director | 46,526 | 0.06% | Jul 30, 2026 |
| Mary L. Smith | Director | 21,813 | 0.03% | Jul 13, 2026 |
| Jessica Caroline Chutter | Director | 7,333 | 0.01% | Mar 26, 2026 |
| Stephanie Okey | Director | 8,000 | 0.01% | Mar 12, 2026 |
| Glenn Jr Md Steele Phd | Director | 22,500 | 0.03% | Jan 6, 2026 |
| David P. Southwell | Director | 22,500 | 0.03% | Jan 6, 2026 |
| Allan Steven Jacobson | Director | 21,451 | 0.03% | Jan 6, 2026 |
| Emma Reeve | Director | 10,666 | 0.01% | Jan 6, 2026 |
| Alethia Young | Director | 21,067 | 0.03% | Jan 6, 2026 |
| Jerome B. Zeldis | Director | 22,500 | 0.03% | Jan 6, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Michael Schmertzler Director | Sep 17, 2026 | Sale(10b5-1 plan) | −9,624 | $67.83 | $652.80K | 1,296,970 |
| Michael Schmertzler Director | Sep 17, 2026 | Sale(10b5-1 plan) | −376 | $68.45 | $25.74K | 1,296,594 |
| Michael Schmertzler Director | Sep 16, 2026 | Sale(10b5-1 plan) | −7,006 | $67.35 | $471.85K | 1,306,594 |
| Michael Schmertzler Director | Sep 16, 2026 | Sale(10b5-1 plan) | −2,994 | $66.58 | $199.34K | 1,313,600 |
| Michael Schmertzler Director | Sep 10, 2026 | Sale(10b5-1 plan) | −10,000 | $67.34 | $673.40K | 1,316,594 |
| Michael Schmertzler Director | Sep 9, 2026 | Sale(10b5-1 plan) | −572 | $68.67 | $39.28K | 1,326,594 |
| Michael Schmertzler Director | Sep 9, 2026 | Sale(10b5-1 plan) | −9,428 | $67.79 | $639.12K | 1,327,166 |
| Michael Schmertzler Director | Aug 27, 2026 | Sale(10b5-1 plan) | −11,890 | $71.55 | $850.73K | 1,337,204 |
| Michael Schmertzler Director | Aug 27, 2026 | Sale(10b5-1 plan) | −610 | $72.22 | $44.05K | 1,336,594 |
| Michael Schmertzler Director | Aug 26, 2026 | Sale(10b5-1 plan) | −5,626 | $73.18 | $411.71K | 1,349,094 |
| Michael Schmertzler Director | Aug 26, 2026 | Sale(10b5-1 plan) | −6,874 | $72.74 | $500.01K | 1,354,720 |
| Michael Schmertzler Director | Aug 20, 2026 | Sale(10b5-1 plan) | −9,419 | $70.78 | $666.68K | 1,364,675 |
| Michael Schmertzler Director | Aug 20, 2026 | Sale(10b5-1 plan) | −2,390 | $71.88 | $171.79K | 1,362,285 |
| Michael Schmertzler Director | Aug 20, 2026 | Sale(10b5-1 plan) | −691 | $72.92 | $50.39K | 1,361,594 |
| Michael Schmertzler Director | Aug 19, 2026 | Sale(10b5-1 plan) | −7,165 | $73.67 | $527.85K | 1,374,094 |
| Michael Schmertzler Director | Aug 19, 2026 | Sale(10b5-1 plan) | −5,335 | $72.86 | $388.71K | 1,381,259 |
| Mark Elliott Boulding EXEC. VP AND CLO | Aug 17, 2026 | Sale(10b5-1 plan) | −1,844 | $72.39 | $133.49K | 106,241 |
| Mark Elliott Boulding EXEC. VP AND CLO | Aug 17, 2026 | Sale(10b5-1 plan) | −969 | $72.90 | $70.64K | 105,272 |
| Mark Elliott Boulding EXEC. VP AND CLO | Aug 17, 2026 | Option exercise | +2,813 | $25.69 | $72.27K | 108,085 |
| Matthew B. Klein CHIEF EXECUTIVE OFFICER, Director | Aug 4, 2026 | Sale(10b5-1 plan) | −10,292 | $68.57 | $705.72K | 383,868 |
| Hege Elisabeth Sollie-Zetlmayer Director | Jul 28, 2026 | Award | +4,000 | – | – | 50,526 |
| Hege Elisabeth Sollie-Zetlmayer Director | Jul 28, 2026 | Award | +2,000 | – | – | 52,526 |
| Pierre Gravier CHIEF FINANCIAL OFFICER | Jul 14, 2026 | Sale(10b5-1 plan) | −3,494 | $80.35 | $280.74K | 83,986 |
| Mary L. Smith Director | Jul 9, 2026 | Sale(10b5-1 plan) | −10,000 | $90.00 | $900.00K | 21,813 |
| Mary L. Smith Director | Jul 9, 2026 | Sale(10b5-1 plan) | −5,834 | $90.00 | $525.06K | 21,813 |
| Mary L. Smith Director | Jul 9, 2026 | Option exercise | +5,834 | $42.95 | $250.57K | 27,647 |
| Mary L. Smith Director | Jul 9, 2026 | Option exercise | +10,000 | $42.95 | $429.50K | 31,813 |
| Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | Jul 9, 2026 | Option exercise | +2,464 | $46.54 | $114.67K | 62,763 |
| Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | Jul 9, 2026 | Sale(10b5-1 plan) | −2,464 | $90.25 | $222.38K | 60,299 |
| Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | Jul 7, 2026 | Option exercise | +24,613 | $39.42 | $970.24K | 84,912 |
| Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | Jul 7, 2026 | Sale(10b5-1 plan) | −3,956 | $87.17 | $344.84K | 80,956 |
| Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | Jul 7, 2026 | Sale(10b5-1 plan) | −11,369 | $89.03 | $1.01M | 69,587 |
| Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | Jul 7, 2026 | Sale(10b5-1 plan) | −9,288 | $89.44 | $830.72K | 60,299 |
| Mark Elliott Boulding EXEC. VP AND CLO | Jul 6, 2026 | Sale(10b5-1 plan) | −645 | $85.84 | $55.37K | 106,017 |
| Mark Elliott Boulding EXEC. VP AND CLO | Jul 6, 2026 | Sale(10b5-1 plan) | −601 | $86.38 | $51.91K | 105,272 |
| Mark Elliott Boulding EXEC. VP AND CLO | Jul 6, 2026 | Option exercise | +2,813 | $46.54 | $130.92K | 108,085 |
| Mark Elliott Boulding EXEC. VP AND CLO | Jul 6, 2026 | Sale(10b5-1 plan) | −387 | $83.10 | $32.16K | 107,698 |
| Mark Elliott Boulding EXEC. VP AND CLO | Jul 6, 2026 | Sale(10b5-1 plan) | −1,036 | $84.41 | $87.45K | 106,662 |
| Mark Elliott Boulding EXEC. VP AND CLO | Jul 6, 2026 | Sale(10b5-1 plan) | −519 | $85.84 | $44.55K | 105,873 |
| Mark Elliott Boulding EXEC. VP AND CLO | Jul 6, 2026 | Sale(10b5-1 plan) | −745 | $86.38 | $64.35K | 105,272 |
| Mark Elliott Boulding EXEC. VP AND CLO | Jul 6, 2026 | Option exercise | +2,266 | $39.42 | $89.33K | 107,538 |
| Mark Elliott Boulding EXEC. VP AND CLO | Jul 6, 2026 | Sale(10b5-1 plan) | −313 | $83.10 | $26.01K | 107,225 |
| Mark Elliott Boulding EXEC. VP AND CLO | Jul 6, 2026 | Sale(10b5-1 plan) | −833 | $84.41 | $70.31K | 106,392 |
| Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | Jul 6, 2026 | Sale(10b5-1 plan) | −10,090 | $86.32 | $870.97K | 60,299 |
| Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | Jul 6, 2026 | Sale(10b5-1 plan) | −8,786 | $85.35 | $749.89K | 70,389 |
| Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | Jul 6, 2026 | Option exercise | +18,876 | $38.10 | $719.18K | 79,175 |
| Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | Jul 6, 2026 | Option exercise | +2,474 | $39.42 | $97.53K | 62,773 |
| Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | Jul 6, 2026 | Sale(10b5-1 plan) | −2,474 | $87.03 | $215.31K | 60,299 |
| Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | Jul 6, 2026 | Option exercise | +811 | $38.10 | $30.90K | 61,110 |
| Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | Jul 6, 2026 | Sale(10b5-1 plan) | −426 | $85.28 | $36.33K | 60,684 |
| Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | Jul 6, 2026 | Sale(10b5-1 plan) | −385 | $86.34 | $33.24K | 60,299 |
| Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | Jun 26, 2026 | Sale(10b5-1 plan) | −7,718 | $85.26 | $658.04K | 60,137 |
| Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | Jun 26, 2026 | Option exercise | +7,718 | $38.10 | $294.06K | 67,855 |
| Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | Jun 26, 2026 | Sale(10b5-1 plan) | −412 | $85.23 | $35.11K | 60,137 |
| Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | Jun 26, 2026 | Option exercise | +412 | $38.10 | $15.70K | 60,549 |
| Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | Jun 25, 2026 | Sale(10b5-1 plan) | −582 | $85.24 | $49.61K | 60,556 |
| Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | Jun 25, 2026 | Option exercise | +1,001 | $38.10 | $38.14K | 61,138 |
| Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | Jun 25, 2026 | Sale(10b5-1 plan) | −100 | $87.00 | $8.70K | 60,137 |
| Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | Jun 25, 2026 | Option exercise | +100 | $39.42 | $3.94K | 60,237 |
| Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | Jun 25, 2026 | Sale(10b5-1 plan) | −11,337 | $86.51 | $980.76K | 60,137 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Mark Elliott Boulding Officer | Oct 9, 2026 | 192 | $12.34K | Oct 9, 2026 | Stock Option Exercise |
| Section Six Partners, L.P. Affiliate of Director | Oct 7, 2026 | 10,000 | $643.50K | Oct 7, 2026 | Automatic Conversion of Preferred Stock into Common Stock Upon IPO |
| Mark Elliott Boulding Officer | Oct 6, 2026 | 435 | $27.91K | Oct 6, 2026 | Stock Option Exercise |
| Mark Elliott Boulding Officer | Oct 5, 2026 | 1,638 | $104.88K | Oct 5, 2026 | Stock Option Exercise |
| Glenn Jr Md Steele Phd Director | Sep 30, 2026 | 12,000 | $781.92K | Sep 30, 2026 | Stock Option Exercise |
| Section Six Partners, L.P. Affiliate of Director | Sep 9, 2026 | 40,000 | $2.74M | Sep 9, 2026 | Automatic Conversion of Preferred Stock into Common Stock Upon IPO |
| Section Six Partners, L.P. Affiliate of Director | Aug 25, 2026 | 50,000 | $3.65M | Aug 19, 2026 | Automatic Conversion of Preferred Stock into Common Stock Upon IPO |
| Schmertzler Michael Director | Aug 19, 2026 | 50,000 | $3.65M | Aug 19, 2026 | Open Market |
| Mark Elliott Boulding Officer | Aug 17, 2026 | 2,813 | $201.69K | Aug 17, 2026 | Stock Option Exercise |
| Matthew B. Klein Officer, Director | Aug 4, 2026 | 10,292 | $705.75K | Aug 4, 2026 | Restricted Stock Vesting |
| Pierre Gravier Officer | Jul 14, 2026 | 3,494 | $280.73K | Jul 14, 2026 | Restricted Stock Vesting |
| Mary L. Smith Director | Jul 9, 2026 | 15,834 | $1.43M | Jul 9, 2026 | Stock Option Exercise |
| Neil Gregory Almstead Officer | Jul 9, 2026 | 2,464 | $222.37K | Jul 9, 2026 | Stock Option Exercise |
| Neil Gregory Almstead Officer | Jul 7, 2026 | 24,613 | $2.19M | Jul 7, 2026 | Stock Option Exercise |
| Mark Elliott Boulding Officer | Jul 6, 2026 | 5,079 | $427.32K | Jul 6, 2026 | Stock Option Exercise |